Osprey Study

What is the Osprey Clinical Research Study?

The Osprey clinical research study is for people with autosomal dominant optic atrophy (ADOA). This study will test a new investigational medicine to evaluate if the study drug (STK-002) is safe, if it causes any side effects, and how the body processes the study drug.

Who can join the Osprey Clinical Research Study?

Study participants may be able to join the study if they meet the following requirements:

• Must be between the ages of 6 and 55 to participate
• Confirmed diagnosis of ADOA

Other study requirements will apply.

What will happen during the study?

Participation in the Osprey study lasts about 12 months. Study participants can expect the following:

• Review & sign the Informed Consent Form
• Screening (~1 month): Receive study health assessments such as blood tests and eye exams to confirm if you qualify for the study.
• Study Drug Injection (1 day): Receive one dose of STK-002 through IVT injection to one eye. You may also receive anesthesia.
• Follow up period (48 weeks): Receive follow up study health assessments such as blood test and eye exams.

Participation in a clinical study is voluntary. You can ask any questions you have and may leave the study at any time, for any reason.